Clinical trial · no report yet · Phase 3
HARMONi-3
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
- NCT05899608 ↗
- Active, not recruiting
- Summit Therapeutics
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 25 | |
| YouTube | 5 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Ivonescimab Injection; Pembrolizumab Injection
- Arms
- Arm A - Ivonescimab and chemotherapy · Experimental
- Arm B - Pembrolizumab and chemotherapy · Active comparator
- Enrollment
- 1,600 (estimated)
- Primary outcomes
- Overall Survival (OS)
- Progression Free Survival (PFS)
- Sponsor
- Summit Therapeutics
- Start
- Oct 26, 2023
- Primary completion
- Dec 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT05899608 · updated Oct 8, 2026